Most-Downgraded Stocks NASDAQ:FATE Fate Therapeutics - FATE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.33 -0.15 (-2.74%) (As of 03/28/2023 10:57 AM ET) Add Compare Share Share Today's Range$5.30▼$5.4750-Day Range$4.88▼$6.8752-Week Range$4.02▼$43.12Volume383,681 shsAverage Volume3.91 million shsMarket Capitalization$523.20 millionP/E RatioN/ADividend YieldN/APrice Target$24.69 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Fate Therapeutics MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside258.0% Upside$19.44 Price TargetShort InterestBearish23.64% of Float Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.10Based on 10 Articles This WeekInsider TradingAcquiring Shares$698,138 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.14) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsMedical Sector256th out of 1,002 stocksBiological Products, Except Diagnostic Industry48th out of 166 stocks 4.1 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 5 buy ratings, 15 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.44, Fate Therapeutics has a forecasted upside of 258.0% from its current price of $5.43.Amount of Analyst CoverageFate Therapeutics has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted23.64% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 15.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 1.7 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have bought 75.98% more of their company's stock than they have sold. Specifically, they have bought $698,138.00 in company stock and sold $396,710.00 in company stock.Percentage Held by Insiders17.34% of the stock of Fate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to grow in the coming year, from ($2.14) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fate Therapeutics (NASDAQ:FATE) StockFate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.Read More Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Stock News HeadlinesMarch 27, 2023 | marketwatch.comNatural Killer Cells Therapeutics Market Outlook By 2031March 27, 2023 | markets.businessinsider.com15 Analysts Have This to Say About Fate TherapeuticsMarch 28, 2023 | Press Research (Ad)Nevada Could be the Source for America's Green FutureIndustry shift towards lithium driven by green energy goalsMarch 27, 2023 | marketwatch.comNK Cell Therapy Market Size and Forecast till 2031March 23, 2023 | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Lifted to Hold at StockNews.comMarch 22, 2023 | americanbankingnews.comBrokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) PT at $20.36March 21, 2023 | businesswire.comFATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the FirmMarch 21, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)March 28, 2023 | Press Research (Ad)Nevada Could be the Source for America's Green FutureIndustry shift towards lithium driven by green energy goalsMarch 20, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Century Therapeutics (IPSC)March 19, 2023 | benzinga.comWEDNESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the FirmMarch 17, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Repare Therapeutics (RPTX)March 10, 2023 | msn.comVanguard Group Now Owns 10.12% of Fate Therapeutics (FATE)March 9, 2023 | markets.businessinsider.comSVB Securities Remains a Hold on F-star Therapeutics (FSTX)March 7, 2023 | benzinga.comNOTICE For Long Term Investors In NASDAQ: FATE: Lawsuit against Fate Therapeutics, Inc. announced by Shareholders FoundationMarch 3, 2023 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | finance.yahoo.comFate Therapeutics Full Year 2022 Earnings: Beats ExpectationsMarch 1, 2023 | benzinga.comFATE SHAREHOLDER NOTICE: Hagens Berman, National...March 1, 2023 | markets.businessinsider.comHere's what Wall Street expects from Fate Therapeutics's earnings reportMarch 1, 2023 | barrons.comFate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business UpdatesMarch 1, 2023 | msn.comFate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93MMarch 1, 2023 | finance.yahoo.comFATE's Q4 Loss Narrower Than Expected, Pipeline in FocusFebruary 27, 2023 | marketwatch.comNK Cell Therapy Market 2023 to 2026 CONSUMER INSIGHTS with Dynamics ScenarioFebruary 23, 2023 | marketwatch.comInduced Pluripotent Stem Cells (iPSCs) Market Size, Share & Trends Analysis Forecast Report by 2028February 22, 2023 | marketwatch.comNatural Killer Cell Therapy Market Size 2023 NEWEST INDUSTRY DATA with Recent Industry Developments till 2028February 21, 2023 | marketwatch.comNatural Killer Cell Therapy Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028February 19, 2023 | benzinga.comFATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud LawsuitSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Company Calendar Last Earnings2/28/2023Today3/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees449Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.44 High Stock Price Forecast$65.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+350.5%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-281,720,000.00 Net Margins-292.55% Pretax Margin-292.55% Return on Equity-50.86% Return on Assets-36.11% Debt Debt-to-Equity RatioN/A Current Ratio4.40 Quick Ratio4.40 Sales & Book Value Annual Sales$96.30 million Price / Sales5.59 Cash FlowN/A Price / Cash FlowN/A Book Value$4.98 per share Price / Book1.10Miscellaneous Outstanding Shares98,160,000Free Float81,141,000Market Cap$537.92 million OptionableOptionable Beta1.53 Key ExecutivesJ. Scott WolchkoPresident, Chief Executive Officer & DirectorEdward J. DulacChief Financial Officer & Accounting OfficerBahram ValamehrChief Research & Development OfficerWen Bo WangSenior Vice President-Technical OperationsYu Waye ChuChief Medical OfficerKey CompetitorsEditas MedicineNASDAQ:EDITHilleVaxNASDAQ:HLVXJATT AcquisitionNYSE:JATTNovavaxNASDAQ:NVAXAlectorNASDAQ:ALECView All CompetitorsInsiders & InstitutionsVictory Capital Management Inc.Sold 221,137 shares on 3/10/2023Ownership: 0.774%NatixisBought 2,871 shares on 2/24/2023Ownership: 0.003%Coppell Advisory Solutions Corp.Bought 4,190 shares on 2/17/2023Ownership: 0.004%Alliancebernstein L.P.Bought 200,000 shares on 2/16/2023Ownership: 0.311%Point72 Middle East FZEBought 39,031 shares on 2/16/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions FATE Stock - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 15 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price forecast for 2023? 22 analysts have issued 1 year price targets for Fate Therapeutics' shares. Their FATE share price forecasts range from $6.00 to $65.00. On average, they expect the company's stock price to reach $19.44 in the next twelve months. This suggests a possible upside of 254.7% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2023? Fate Therapeutics' stock was trading at $10.09 on January 1st, 2023. Since then, FATE stock has decreased by 45.7% and is now trading at $5.48. View the best growth stocks for 2023 here. Are investors shorting Fate Therapeutics? Fate Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 21,580,000 shares, an increase of 15.6% from the February 28th total of 18,660,000 shares. Based on an average daily trading volume, of 4,010,000 shares, the short-interest ratio is currently 5.4 days. Approximately 23.6% of the shares of the stock are short sold. View Fate Therapeutics' Short Interest. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) posted its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.28. The biopharmaceutical company earned $44.36 million during the quarter, compared to analysts' expectations of $18.41 million. Fate Therapeutics had a negative net margin of 292.55% and a negative trailing twelve-month return on equity of 50.86%. The business's quarterly revenue was up 159.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.72) EPS. What ETFs hold Fate Therapeutics' stock? ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), Direxion Daily S&P Biotech Bull 3x Shares (LABU), AI Powered Equity ETF (AIEQ), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ROBO Global Healthcare Technology and Innovation ETF (HTEC). What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (4.34%), Millennium Management LLC (2.95%), Price T Rowe Associates Inc. MD (2.74%), Renaissance Technologies LLC (1.86%), Morgan Stanley (1.79%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $5.48. How much money does Fate Therapeutics make? Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $537.92 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. How many employees does Fate Therapeutics have? The company employs 449 workers across the globe. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com. This page (NASDAQ:FATE) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.